DC-HIL+ CD14+ HLA-DR no/low cells are a potential blood marker and therapeutic target for melanoma

J Invest Dermatol. 2014 Nov;134(11):2839-2842. doi: 10.1038/jid.2014.248. Epub 2014 Jun 16.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Aged
  • Biomarkers, Tumor / blood
  • Biomarkers, Tumor / immunology
  • Disease Progression
  • Dysplastic Nevus Syndrome / blood
  • Dysplastic Nevus Syndrome / immunology
  • Female
  • HLA-DR Antigens / blood*
  • HLA-DR Antigens / immunology
  • Humans
  • Lipopolysaccharide Receptors / blood*
  • Lipopolysaccharide Receptors / immunology
  • Male
  • Melanoma / blood*
  • Melanoma / immunology
  • Melanoma / therapy
  • Membrane Glycoproteins / blood*
  • Membrane Glycoproteins / immunology
  • Middle Aged
  • Neoplasm Metastasis
  • Skin Neoplasms / blood*
  • Skin Neoplasms / immunology
  • Skin Neoplasms / therapy

Substances

  • Biomarkers, Tumor
  • GPNMB protein, human
  • HLA-DR Antigens
  • Lipopolysaccharide Receptors
  • Membrane Glycoproteins